Back to Search
Start Over
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
- Source :
-
Gynecologic oncology [Gynecol Oncol] 2022 Feb; Vol. 164 (2), pp. 398-405. Date of Electronic Publication: 2021 Nov 29. - Publication Year :
- 2022
-
Abstract
- Background: Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.<br />Methods: Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.<br />Results: One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).<br />Conclusions: Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.<br /> (Copyright © 2021. Published by Elsevier Inc.)
- Subjects :
- Adenocarcinoma drug therapy
Adenocarcinoma pathology
Black or African American statistics & numerical data
Age Factors
Aged
Aged, 80 and over
Asian statistics & numerical data
Carboplatin administration & dosage
Carcinoma, Endometrioid drug therapy
Carcinoma, Endometrioid pathology
Carcinoma, Ovarian Epithelial pathology
Fallopian Tube Neoplasms drug therapy
Fallopian Tube Neoplasms pathology
Female
Hispanic or Latino statistics & numerical data
Humans
Middle Aged
Neoplasm Staging
Neoplasms, Cystic, Mucinous, and Serous pathology
Ovarian Neoplasms pathology
Paclitaxel administration & dosage
Peritoneal Neoplasms drug therapy
Peritoneal Neoplasms pathology
Prognosis
Proportional Hazards Models
Survival Rate
White People statistics & numerical data
Angiogenesis Inhibitors therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bevacizumab therapeutic use
Carcinoma, Ovarian Epithelial drug therapy
Chemotherapy, Adjuvant methods
Ethnicity statistics & numerical data
Neoplasms, Cystic, Mucinous, and Serous drug therapy
Ovarian Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1095-6859
- Volume :
- 164
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Gynecologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 34857397
- Full Text :
- https://doi.org/10.1016/j.ygyno.2021.11.013